BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasia
Third-quarter revenue rose 32% to $1.025 billion as FDA set a May 30, 2027 action date for VOXZOGO in HCH and BioMarin added a new Fabry asset to its pipeline.
SEC filing (2)